24855-58-1

Usage

Uses

Used in Veterinary Medicine:
4-hydroxy-3-nitrobenzenesulphonamide is used as an antiprotozoal and antibacterial agent for the treatment of coccidiosis in poultry. It serves to prevent and treat parasitic infections in animals, particularly focusing on the control of protozoan parasites that cause significant health issues in livestock.
Used in Poultry Industry:
In the poultry industry, 4-hydroxy-3-nitrobenzenesulphonamide is used as a prophylactic and therapeutic agent to combat coccidiosis, a disease caused by the protozoan Eimeria. Its application helps in maintaining the health and productivity of poultry, thereby ensuring a stable food supply and contributing to the economic viability of the industry.
Used in Parasite Control:
4-hydroxy-3-nitrobenzenesulphonamide is used as a parasiticide in veterinary medicine to control various parasitic infections in animals. Its antimicrobial action aids in reducing the prevalence and impact of parasitic diseases, thus improving the overall health and well-being of animals under veterinary care.

InChI:InChI=1/C6H6N2O5S/c7-14(12,13)4-1-2-6(9)5(3-4)8(10)11/h1-3,9H,(H2,7,12,13)

Upstream product

• 1576-43-8 4-hydroxybenzenesulphonamide 
• 2360-19-2 4-amino-3-nitrobenzenesulfonamide 
• 16761-19-6 4-acetylamino-3-nitro-benzenesulphonyl chloride 
• 39234-94-1 4-acetylamino-3-nitro-benzenesulfonic acid amide 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 

Downstream Products

• 1228782-61-3 4-(3-(dimethylamino)propoxy)-3-nitrobenzenesulfonamide 
• 91559-86-3 6,6'-Dihydroxy-3,3'-disulfamoyl-diphenyl-disulfid 
• 90090-44-1 4-Methoxy-3-methylmercapto-benzolsulfonsaeure-amid 
• 88393-80-0 4-Methoxy-3-mercapto-benzolsulfonsaeure-amid 
• 98-32-8 3-amino-4-hydroxybenzenesulfonamide 

Relevant academic research and scientific papers

Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani

Chagas disease and leishmaniasis are neglected tropical disorders caused by the protozoans Trypanosoma cruzi and Leishmania spp. Carbonic anhydrases (CAs, EC 4.2.1.1) from these protozoans (α-TcCA and β-LdcCA) have been validated as promising targets for chemotherapic interventions. Many anti-protozoan agents, such as nitroimidazoles, nifurtimox, and benznidazole possess a nitro aromatic group in their structure which is crucial for their activity. As a continuation of our previous work on N-nitrosulfonamides as anti-protozoan agents, we investigated benzenesulfonamides bearing a nitro aromatic moiety against TcCA and LdcCA, observing selective inhibitions over human off-target CAs. Selected derivatives were assessed in vitro in different developmental stages of T. cruzi and Leishmania spp. A lack of significant growth inhibition has been found, which has been connected to the low permeability of this class of derivatives through cell membranes. Further strategies necessarily need to be designed for targeting Chagas disease and leishmaniasis with nitro-containing CA inhibitors.

4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles

Human carbonic anhydrases (CA, EC, 4.2.1.1) IX and XII are overexpressed in cancer cells as adaptive response to hypoxia and acidic conditions characteristic of many tumors. In addition, hypoxia facilitates the activity of specific oxido-reductases that may be exploited to selectively activate bioreductive prodrugs. Here, new selective CA IX/XII inhibitors, as analogues of the antitumor phase II drug SLC-0111 are described, namely ureido-substituted benzenesulfonamides appended with a nitro-aromatic moiety to yield an antiproliferative action increased by hypoxia. These compounds were screened for the inhibition of the ubiquitous hCA I/II and the target hCA IX/XII. Six X-ray crystallographies with CA II and IX/mimic allowed for the rationalization of the compounds inhibitory activity. The effects of some such compounds on the viability of HT-29, MDA-MB-231, and PC-3 human cancer cell lines in both normoxic and hypoxic conditions were examined, providing the initiation toward the development of hypoxia-activated antitumor CAIs.